Utility of Humanized Immune System Mice for Metastatic Cancer Drug Development

Tuesday, May 4 at 11 a.m. ET / 5 p.m. CET

Register Now


Access exclusive, in-depth guides and thought leadership content curated by our scientific experts.

View All


Have a specific model?
Use our advanced search tool by entering a model name or number

Our Capabilities and Services

More Than 4,500 Genetically Engineered Mice & Rat Models

Global Harmonization of Health Standards and True Gnotobiotic Profiles

Custom Model Generation & Colony Management Solutions

Scientific Leadership & Ecosystem of Support

  • Humanized FKBP5 Mouse Models Support Study of Psychiatric Disorders

    Psychiatric disorders, including depression, bipolar disorder, and schizophrenia, are multifactorial and polygenic. The underlying risks for these diseases are increasingly linked in epidemiologic studies to the complex interplay between genetic and environmental factors. These risk factors can act cumulatively throughout a patient's lifetime, with adverse... Read more

  • The Issue of Sex vs. Gender in Preclinical Animal Model Studies

    In science, it is of the utmost importance to be precise and accurate with language. It is not uncommon for scientists to operationalize, or define, a term that may vary in meaning across different contexts or research groups. However, when scientists use words incorrectly or... Read more

  • Considerations for Performing a Successful Syngeneic Tumor Study

    As the focus of cancer treatment has shifted—from directly targeting and destroying a tumor to leveraging the body's immune system to fight the tumor—there has been a corresponding change in how researchers use animal models in their preclinical oncology studies. While xenograft studies utilizing immunodeficient... Read more

  • BALB/c Il10 Knockout Mice are Useful Tools for IBD and Colitis Research

    Janus kinase (JAK) inhibitors are a promising recent addition to the inflammatory bowel disease (IBD) armamentarium. Tofacitinib, a small molecule pan-JAK inhibitor, received FDA approval in 2018 for the treatment of adult patients with moderate-to-severe ulcerative colitis1. Tofacitinib is non-selective and inhibits all four JAK... Read more

  • Inosine, a Microbiome Metabolite, Affects the Efficacy of Checkpoint Inhibitor Therapy

    Drugs targeting immune checkpoint inhibitor pathways have shown tremendous promise in treating various types of cancer and have been highly effective in a number of patients. However, for a subset of cancer patients this new type of treatment approach has failed to work. Recently, a... Read more

  • Antibody-deficient mice overcome obstacles to efficacy testing of biologics

    Learn how the Jh Mouse Supports Syngeneic Studies Structure of EMD Serono's bifunctional immune-oncology therapeutic M7824, from Lan et al.3 Immunogenicity can obscure efficacy in early preclinical research Biologic drugs such as monoclonal antibodies or RNA therapies can trigger immune reactions (immunogenicity) upon treatment. Such... Read more

  • How the Microbiome Affects Efficacy for Immune Checkpoint Inhibitors

    As researchers continue to explore the complex relationship between the microbiome and disease, a key point of focus is understanding how the microbiome impacts drug efficacy. Both preclinical and clinical findings increasingly demonstrate that the microbiome can impact how therapeutics work — as well as... Read more

  • A Guide to Monitoring NASH Progression in Diet-Induced Mouse Disease Models

    Numerous diet-based models have been developed to induce nonalcoholic fatty liver disease and steatohepatitis (NAFLD/NASH) in mice. Chronic consumption of high-energy feeds enriched with fat causes steatotic buildup, lipotoxic inflammation, hepatic dysfunction, and liver fibrosis. Next generation diets1 include fructose and cholesterol as accelerants toward... Read more


Welcome! Tell us a little about yourself